Savvy Stock Picks

Patterson-UTI Energy, Inc. (Public, NASDAQ:PTEN) increased 0.09%, to close at $21.38 and its overall traded volume was 2.00M shares during the last session against its average volume of 3.44M. PTEN opened the day at $21.41, it made an intraday low of $21.02 and an intraday high of $21.53. The stock has a 52 week low of $11.85 and 52 week high of $22.67. PTEN’s market capitalization is 3.30B and it has 154.13M outstanding shares.

About Patterson-UTI Energy, Inc. (Public, NASDAQ:PTEN)
Patterson-UTI Energy, Inc. (Patterson-UTI) owns and operates fleets of land-based drilling rigs in the United States. The Company’s contract drilling business operates primarily in Texas, New Mexico, Oklahoma, Arkansas, Louisiana, Mississippi, Colorado, Utah, Wyoming, Montana, North Dakota, Pennsylvania, West Virginia and western Canada. As of December 31, 2009, it had a drilling fleet that consisted of 341 marketable land-based drilling rigs. It provides pressure pumping services to oil and natural gas operators primarily in the Appalachian Basin. These services consist primarily of well stimulation and cementing for completion of new wells and remedial work on existing wells. It also owns and invests in oil and natural gas assets as a working interest owner. Its oil and natural gas interests are located primarily in Texas and New Mexico. The Company exited the drilling and completion fluids services business on January 20, 2010, and sold substantially all of the assets.

SatCon Technology Corporation (Public, NASDAQ:SATC) increased 1.52%, to close at $4.34 and its overall traded volume was 2.00M shares during the last session against its average volume of 2.06M. SATC opened the day at $4.31, it made an intraday low of $4.20 and an intraday high of $4.36. The stock has a 52 week low of $2.19 and 52 week high of $4.53. SATC’s market capitalization is 506.30M and it has 116.79M outstanding shares.

About SatCon Technology Corporation (Public, NASDAQ:SATC)
Satcon Technology Corporation (Satcon) is a clean energy technology provider of utility grade power solutions for the renewable and distributed energy markets. The Company delivers power conversion solutions and system design services for large-scale renewable energy plants. Satcon’s products are utilized by businesses and utility companies to convert renewable energy sources into electrical power. It also offers system design services and solutions for management, monitoring, and performance measurement. The Company produces a range of products to provide the bridge between clean energy sources and large-scale power grids. Its solutions for renewable energy consist of two core product offerings: Utility Grade Inverters for Solar Photovoltaic and Fuel Cell Applications and Micro Grid Solutions. Subsequent to the year ended December 31, 2009, the Company sold its Applied Technology business unit.

Genzyme Corporation (Public, NASDAQ:GENZ) decreased -0.20%, to close at $69.65 and its overall traded volume was 2.00M shares during the last session against its average volume of 2.77M. GENZ opened the day at $70.00, it made an intraday low of $69.55 and an intraday high of $70.14. The stock has a 52 week low of $45.39 and 52 week high of $73.23. GENZ’s market capitalization is 18.04B and it has 258.99M outstanding shares.

About Genzyme Corporation (Public, NASDAQ:GENZ)
Genzyme Corporation (Genzyme) is a biotechnology company. The Company’s product and service portfolio is focused on rare genetic disease disorders, renal diseases, orthopaedics, cancer, transplant and immune disease. Genzyme operates in four business segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology. Genetic Diseases unit develops, manufactures and distributes therapeutic products, with a focus on products to treat patients suffering from genetic diseases, including a family of diseases known as lysosomal storage disorders (LSDs). Cardiometabolic and Renal segment develops, manufactures and distributes products that treat patients suffering from renal diseases, including chronic renal failure and endocrine and cardiovascular diseases. Biosurgery develops, manufactures and distributes biotherapeutics and biomaterial-based products. Hematologic Oncology develops, manufactures and distributes products for the treatment of cancer.

SunPower Corporation (Public, NASDAQ:SPWRA) decreased -3.14%, to close at $13.10 and its overall traded volume was 1.98M shares during the last session against its average volume of 2.32M. SPWRA opened the day at $13.49, it made an intraday low of $13.02 and an intraday high of $13.49. The stock has a 52 week low of $9.61 and 52 week high of $26.35. SPWRA’s market capitalization is 1.28B and it has 97.90M outstanding shares.

About SunPower Corporation (Public, NASDAQ:SPWRA)
SunPower Corporation (SunPower) is a vertically integrated solar products and services company that designs, manufactures and markets high-performance solar electric power technologies. The Company operates through two business segments: components segment and systems segment. The Systems Segment represents sales directly to system owners and developers and includes engineering, procurement, construction (EPC) and other services relating to solar electric power systems that integrate the Company’s solar panels and balance of systems components, as well as materials sourced from other manufacturers. The Components Segment primarily represents sales of the Company’s solar panels and inverters to solar systems installers and other resellers, including the Company’s third-party global dealer network. On April 14, 2009, the Company completed the acquisition of Tilt Solar. In March 2010, the Company acquired SunRay Renewable Energy.

Amylin Pharmaceuticals, Inc. (Public, NASDAQ:AMLN) decreased -0.92%, to close at $15.09 and its overall traded volume was 1.98M shares during the last session against its average volume of 2.13M. AMLN opened the day at $15.29, it made an intraday low of $14.93 and an intraday high of $15.38. The stock has a 52 week low of $9.51 and 52 week high of $24.21. AMLN’s market capitalization is 2.17B and it has 144.00M outstanding shares.

About Amylin Pharmaceuticals, Inc. (Public, NASDAQ:AMLN)
Amylin Pharmaceuticals, Inc. (Amylin) is a biopharmaceutical company engaged in discovery, development and commercialization of medicines. The Company is marketing two first-in-class medicines to treat diabetes, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. It has an agreement with Eli Lilly and Company (Lilly), for the global development and commercialization of exenatide. This agreement includes BYETTA and other formulations of exenatide, such as exenatide once weekly. SYMLIN is an approved medicine in a class of compounds called amylinomimetics. BYETTA is an approved medicine in a class of compounds called glucagon-like peptide-1 (GLP-1) receptor agonists. In October 2009, the Company received approval for the expanded indication of BYETTA injection as a first-line, stand-alone treatment (monotherapy) for type II diabetes.